Redx Pharma (LON:REDX) Stock Crosses Above 50 Day Moving Average of $13.67

Redx Pharma Plc (LON:REDX) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 13.67 ($0.17) and traded as high as GBX 33 ($0.42). Redx Pharma shares last traded at GBX 15 ($0.19), with a volume of 1,420,135 shares changing hands.

Redx Pharma Trading Up 31.6 %

The stock has a market cap of £58.35 million, a PE ratio of -150.00 and a beta of -0.53. The stock has a 50-day moving average price of GBX 13.57 and a two-hundred day moving average price of GBX 18.88. The company has a debt-to-equity ratio of 527.00, a current ratio of 1.11 and a quick ratio of 1.93.

Insiders Place Their Bets

In other news, insider Lisa Anson acquired 399,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was bought at an average cost of GBX 8 ($0.10) per share, for a total transaction of £31,920 ($40,569.40). 18.35% of the stock is owned by corporate insiders.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.